pharma · Duchenne Muscular Dystrophy · Muscular Dystrophies · CAPR
CAPRICOR THERAPEUTICS
CAPRICOR THERAPEUTICS, INC.
CAPRICOR THERAPEUTICS clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2005
- Employees
- 240
- Programs
- 8
- Drugs
- 6
- Patents
- 43
CAPRICOR THERAPEUTICS projects
6 ClinicalTrials.gov programs sponsored by CAPRICOR THERAPEUTICS.
CAPRICOR THERAPEUTICS has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Allogeneic Cardiosphere-Derived Cells (CAP-1002)
CAPRICOR THERAPEUTICS, INC.
Duchenne Muscular Dystrophy
2 trials -
CAP-1002
CAPRICOR THERAPEUTICS, INC.
Covid19
1 trial -
CAP-1002
CAPRICOR THERAPEUTICS, INC.
Muscular Dystrophies
1 trial -
CAP-1002 Allogeneic Cardiosphere-Derived Cells
CAPRICOR THERAPEUTICS, INC.
Myocardial Infarction
1 trial -
Cenderitide
CAPRICOR THERAPEUTICS, INC.
Heart Failure
2 trials -
Deramiocel (CAP-1002)
CAPRICOR THERAPEUTICS, INC.
Duchenne Muscular Dystrophy
1 trial
Frequently asked questions
How many clinical projects does CAPRICOR THERAPEUTICS have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.